CD1d-restricted invariant natural killer T (iNKT) cells have diverse immune stimulatory/regulatory activities through their ability to release cytokines and to kill or transactivate other cells. Activation of iNKT cells can protect against multiple diseases in mice but clinical trials in humans have had limited impact. Clinical studies to date have targeted polyclonal mixtures of iNKT cells and we proposed that their subset compositions will influence therapeutic outcomes. We sorted and expanded iNKT cells from healthy donors and compared the phenotypes, cytotoxic activities and cytokine profiles of the CD4 + , CD8a + and CD4 2 CD8a 2 double-negative (DN) subsets. CD4 + iNKT cells expanded more readily than CD8a + and DN iNKT cells upon mitogen stimulation. CD8a
Introduction
Invariant natural killer T (iNKT) cells are cytotoxic T lymphocytes that express NK cell markers and a T cell receptor (TCR) composed of an invariant a-chain (Va24Ja18 in humans and Va14Ja18 in mice) paired with one of a limited number of bchains. iNKT cells recognize glycolipid antigens presented by the major histocompatibility complex class I-like molecule CD1d [1, 2] . They can recognize a number of self and bacterial glycolipids [3, 4] but the most potent activator of iNKT cells known to date is the marine sponge-derived glycolipid agalactosylceramide (a-GalCer) [5] . Upon activation with aGalCer, iNKT cells can kill a wide range of tumor cell lines [6, 7] and secrete a diverse range of growth factors and cytokines that activate and polarize adaptive immune responses [1, 2, [8] [9] [10] [11] [12] . Activated iNKT cells can also interact directly with other cells of the immune system and can induce the maturation of dendritic cells (DC) into antigen-presenting cells (APC) [13] [14] [15] and of B cells into antibody-secreting plasma cells [16, 17] . Therapeutic activation of iNKT cells in murine models can prevent tumor growth, ameliorate autoimmune disease and protect against microbial infection [6, [18] [19] [20] . Numerical and functional iNKT cell deficiencies have been reported in a number of human diseases [21] [22] [23] [24] [25] , but clinical trials that have targeted iNKT cells in humans have to date been somewhat disappointing [26] [27] [28] [29] [30] .
A reason for the low efficacy of iNKT cells in human immunotherapy may lie in their multifunctionality. a-GalCeractivated iNKT cells can rapidly and simultaneously secrete large amounts of Th1 and Th2 cytokines, such as interferon-c (IFN-c), tumor necrosis factor-a (TNF-a), IL-4 and IL-13 [1, 8, 9] and can be induced under certain conditions to release the regulatory T cell (Treg) cytokine IL-10 and the Th17 cytokines IL-17 and IL-22 [10] [11] [12] 31] . This multiplicity of cytokine production, which includes cytokines with opposing or mutually-inhibitory roles in immune responses, may be counter-productive in therapeutic applications where polarized adaptive immunity is desired. For example, the antitumor activity of iNKT cells is associated with their secretion of Th1 cytokines, however, Th2/Treg cytokines released by iNKT cells may dampen antitumor immunity and even promote tumor growth [19, 22, [32] [33] [34] . To overcome this problem, several groups have synthesized a-GalCer analogues that can selectively skew iNKT cell responses towards Th1 [35, 36] or Th2 [37, 38] .
Within iNKT cells there are distinct subsets based on CD4 and CD8 expression and most studies have focused on iNKT cells with CD4 + CD8b 2 (CD4 + ) and CD4 2 CD8b 2 (CD4 2 ) phenotypes, the main subsets seen in mice [1, 2] . However, it has become clear that human CD4
2 iNKT cells in humans can be sub-classified into CD4 [39] [40] [41] [42] [43] [44] . These iNKT cell subsets are reported to have distinct immunological properties, with CD4
+ iNKT cells releasing both Th1 and Th2 cytokines and CD8a
+ and DN iNKT cells exhibiting Th1 phenotypes [9, 15, 39, [45] [46] [47] [48] and cytotoxic activity [39] [40] [41] [42] [43] [44] . Altered iNKT cell subset frequencies and functions have been described in humans with disease [21, 22, 24, 44, 48, 49] . Phase I clinical studies in cancer patients involving in vivo administration of a-GalCer or infusion of ex vivo expanded and activated iNKT cells have generally not considered the subset composition of iNKT cells being activated [26] [27] [28] [29] [30] , which we hypothesize could play an important role in clinical outcome. In the present study we expanded iNKT cells ex vivo from healthy individuals and systematically compared the phenotypes, cytotoxic activities and cytokine profiles of the CD4 + , DN and CD8a + iNKT subsets. We report that all expanded iNKT cell subsets can kill CD1d
+ target cells and release Th1 and Th2 cytokines, but CD8a
+ iNKT cells display the most potent Th1/cytolytic activity while CD4
+ iNKT cells release the most Th2 cytokines. All iNKT cell subsets similarly upregulate CD40L upon activation and induce cytokine secretion by DC, while only the CD4 + iNKT cell subset releases IL-9 and IL-10. Thus, CD8a
+ iNKT cells may be ideal candidates for future iNKT cell-based cancer therapies, whereas the immunoregulatory properties of CD4 + iNKT cells could be beneficial for the treatment of inflammatory or autoimmune diseases.
Materials and Methods

Ethics Statement
This study was approved by the Research Ethics Committee of St. James's Hospital and the Adelaide and Meath Hospitals incorporating the National Children's Hospital (SJH/AMNCH), Dublin. Informed written consent was obtained from all study participants except when anonymised used buffy coat packs (obtained from the Irish Blood Transfusion Service) were used.
Antibodies and flow cytometry
Fluorochrome-conjugated monoclonal antibodies (mAb) specific for human CD1d, CD3, CD4, CD8a, CD8b, CD11c, CD14, CD25, CD56, CD107a, CD154 (CD40L), CD161, HLA-DR, NKG2D, the Va24 and Vb11 chains that form the TCR present on iNKT cells and the complementarity-determining region 3 of the invariant Va24Ja18 TCR chain (6B11) were obtained from BD Biosciences (Oxford, UK), Immunotools (Friesoythe, Germany), eBioscience (Hatfield, UK), Biolegend (San Diego, CA) or Beckman Coulter (Galway, Ireland). Cells were stained with mAbs in phosphate buffered saline containing 1% bovine serum albumin and 0.02% sodium azide and analysed using a CyAn ADP flow cytometer (Beckman Coulter, High Wycombe, UK) and FlowJo software (Treestar, Ashland, OR). For FoxP3 staining, the FoxP3 staining buffer kit (eBioscience) was used following manufacturer's instructions. For CD40L staining, cells were co-cultured for 6 hours with CD1d
+ APC pulsed with a-GalCer (see below) in the presence of anti-CD40L mAb and 1 mM monensin (SigmaAldrich, Poole, UK) as described previously [50] . Cells were then stained with 6B11, CD4 and CD8a and analysed by flow cytometry. Single stained controls were used to set compensation parameters and fluorescence-minus-one controls were used to set gates.
Ex vivo expansion of iNKT cells
Peripheral blood mononuclear cells (PBMC) were prepared from unselected buffy coat packs by density gradient centrifugation over Lymphoprep (Nycomed Pharma, Oslo, Norway). iNKT cells were enriched from PBMC by magnetic bead separation using 6B11 coated magnetic beads (Miltenyi Biotec, Bergisch-Gladbach, Germany). iNKT cells were then purified by cell sorting of CD3 + Va24 + Vb11 + cells using a MoFlo TM XDP Cell Sorter (Beckman Coulter). Sorted iNKT cells were expanded by culturing 1,000 iNKT cells in iNKT cell medium (RPMI 1640 containing 0.05 mM L-glutamine, 10% HyClone FCS, 1% penicillinstreptomycin, 1% fungizone 25 mM HEPES, 50 mM 2-mercaptoethanol, 1 mM sodium pyruvate, 1% non-essential amino acids mixture and 1% essential amino acids mixture; Gibco-BRL, Paisley, UK and Thermo-Scientific, Logan, UT) and stimulating them with 1 mg/ml phytohemaggluttinin-P (PHA-P; SigmaAldrich, Dublin, Ireland) and 250 U/ml IL-2 (R&D Systems, Abingdon, UK) in the presence of an excess (2610 5 ) irradiated allogeneic PBMC prepared from two donors. After 24 hours and again after 48 hours, medium was replaced with fresh iNKT cell medium containing 250 U/ml IL-2. Cells were expanded for a minimum of 3 weeks before being used in experiments.
Generation of monocyte derived DC
Monocytes were enriched to .90% purity from PBMC isolated from buffy coat packs by positive selection using CD14 Microbeads (Miltenyi Biotec). The monocytes were allowed to differentiate into immature DC (iDC) by culturing them at densities of 10 6 cells/ml using 3 ml/well of a 6-well plate (Corning, Amsterdam, Netherlands) in complete RPMI medium (RPMI 1640 containing 0.05 mM L-glutamine, 1% penicillin-streptomycin, 1% fungizone, 25 mM HEPES made with low-endotoxin fetal calf serum) containing 50 ng/ml granulocyte-macrophage colony-stimulating factor (GM-CSF) and 70 ng/ml IL-4. Cells were cultured for 6 days, replacing with fresh medium containing cytokines on day 3. On day 6, iDC were removed from the wells by aspiration using a wide-gauge Pasteur pipette and washed with warm RPMI medium. Flow cytometry was used to verify that differentiation into iDC had taken place and cells expressed HLA-DR and CD11c but not CD14.
In vitro stimulation of iNKT cells with a-GalCer
iNKT cells were stimulated in vitro with a variety of a-GalCerpulsed APC, including iDC, CD1d-transfected HeLa [36] or C1R [8] cells (hereafter referred to as HeLa-CD1d and C1R-CD1d) or the CD1d + T cell line, Jurkat. As controls, mock-transfected HeLa and C1R cells (HeLa-mock and C1R-mock) and the CD1d 2 cell line K562 were also used. In addition, PBMC from two consenting patients with B cell chronic lymphocytic leukemia (B-CLL) were obtained with ethical permission from the Haematology Clinic at St. James's Hospital, Dublin.
a-GalCer (KRN7000) was purchased from Funakoshi Co. Ltd, (Tokyo, Japan) and reconstituted in 100% DMSO at a concentration of 1 mg/ml followed by heating to 80uC for 2 minutes, sonication for 15 minutes and vortexing for 5 minutes. This concentrated stock was aliquoted and stored at 270uC. For use in iNKT cell assays, stock a-GalCer was thawed followed by heating to 80uC for 2 minutes, sonication for 10 minutes and vortexing for 1 minute. Dilution to the required concentration was then made in 37uC pre-warmed iNKT cell medium followed by heating to 80uC for 2 minutes, sonication for 5 minutes and vortexing for 1 minute. Required dilutions thereafter were made in 37uC pre-warmed medium followed by vigorous vortexing. The above-mentioned cell lines were pulsed for 18 hours with the appropriate concentrations of a-GalCer to allow for antigen processing and presentation. Medium was then removed before the addition of iNKT cells as described below.
Cytotoxicity assays
Cytolytic degranulation of iNKT cells cultured with a-GalCerpulsed APC was examined by flow cytometric analysis of CD107a expression by iNKT subsets after electronically gating on CD4 + , DN and CD8a
+ iNKT cells. iNKT cells and target cells were co-cultured for 4 hours at 1:1 ratios in the presence of anti-CD107a FITC mAb and monensin (25 mM) was added after 1 hour to prevent proteolysis of the mAb conjugate upon reinternalization of CD107a.
To confirm that CD107a expression directly correlated with target cell death, the flow cytometry-based Total Cytotoxicity and Apoptosis Detection Kit (Immunochemistry Technologies, Bloomington, MN) was used to quantify target cell death. Target cells were incubated with carboxyfluorescein succinimidyl ester (CFSE) following the manufacturer' instructions and incubated with sorted iNKT cell subsets at a ratio of 5:1 for 4 hours at 37uC with 5% CO 2 . After incubation, cells were harvested and 7-aminoactinomycin D (7-AAD), which is excluded by viable cells but can penetrate cell membranes of dying or dead cells, was added and cells were analysed immediately by flow cytometry. CFSE + cells which stained positive for 7-AAD are deemed to be killed target cells.
Analysis of cytokine secretion
To measure cytokine secretion by iNKT subsets, 10 5 sorted CD4 + , DN or CD8a + iNKT cells were stimulated with medium alone, equal numbers of iDCs or HeLa-CD1d (pulsed with aGalCer or vehicle) or 10 ng/ml of phorbol mristate acetate (PMA) and 1 mg/ml of ionomycin (both from Sigma-Aldrich) for 24 hours. The Human Th1/Th2/Th9/Th17/Th22 13plex FlowCytomix Multiplex kit (eBioscience) was used to measure levels of IFN-c, TNF-a, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p70, IL-13, IL-17a and IL-22 in the cell supernatants, following manufacturer's instructions. Results were acquired by flow cytometry and analysed using FlowCytomix pro 2.2 software (eBioscience). In some experiments, cell supernatants were assayed for selected cytokines by enzyme-linked imunosorbent assays (ELISA) using antibody pairs purchased from R&D Systems (Abingdon, UK).
Intracellular analysis of cytokine production by iNKT subsets
iNKT cells were stimulated for 4 hours with equal numbers of HeLa-CD1d cells pulsed with aGalCer or vehicle as described above in the presence of brefeldin A (10 mg/ml, Sigma-Aldrich) to promote intracellular accumulation of cytokines. Cells were harvested and stained for cell surface expression of 6B11, CD4 and CD8a and intracellular expression of IFN-c and IL-4 using fluorochrome-conjugated mAb obtained from BD Biosciences or eBioscience and analysed by flow cytometry.
Statistical analysis
Statistical analysis was carried out using Prism GraphPad Version 5.0. The Kruskal-Wallis test was used to compare unpaired data in 3 groups and Dunn's multiple comparison tests were performed post-hoc to compare individual groups within an experiment. *, ** and *** represent p,0.05, p,0.01 and p#0.001 respectively.
Results
Human CD4
+ iNKT cells expand more readily than CD8a + and DN iNKT cells in response to mitogen stimulation
The distributions of CD4 + , DN and CD8a + iNKT cells in freshly-isolated PBMC and among in vitro expanded iNKT cells from healthy donors were examined by flow cytometric analysis of Va24
+
Vb11
+ CD3 + cells. Since iNKT cells generally comprise ,0.1% of total peripheral T cells [21, 25] (Fig. 1A) , phenotypic analysis of fresh iNKT cells required prior enrichment of iNKT cells from PBMC by magnetic bead separation followed by immediate phenotyping for CD4 and CD8a (Fig. 1B) . The enriched iNKT cells were then further purified by cell sorting and expanded in vitro with PHA-P, irradiated feeders and IL-2 for three weeks. This method resulted in a several thousand-fold increase in iNKT cell numbers with $98% expressing Va24 (Fig. 1C) 
CD8a
+ iNKT cells were also observed in freshly-isolated iNKT cell preparations (Fig. 1B) . Polyclonal lines of iNKT cells were used in flow cytometry-based functional assays where electronic gating of CD4 + , DN and CD8a + expression allowed analysis of the individual subsets. For cytoxicity and cytokine secretion assays, expanded iNKT subsets were further sorted giving highly pure (.98%) populations of CD4 + , DN and CD8a + iNKT cells (Fig. 1F) .
Expanded CD4
+ , DN and CD8a + iNKT cells are phenotypically distinct iNKT lines from up to 5 healthy donors were stained with mAbs specific for the Va24Ja18 TCR (6B11), CD4, CD8a and either the NK cell markers CD56, CD161 or NKG2D or the IL-2 receptor a-chain CD25. The proportions of gated CD4 + , DN and CD8a + iNKT cells that express these markers are shown in Figure 2A . CD56 was found to be expressed by significant numbers of CD8a + iNKT cells but only by a minority of CD4 + iNKT cells ( Fig. 2A ). Since activated, but not resting, helper T cells express CD40L (CD154) [50] , iNKT lines from 3 healthy donors were cocultured for 6 hours with HeLa-CD1d cells pulsed with varying concentrations of a-GalCer (0-1,000 ng/ml) in the presence of monensin and anti-CD40L mAb. Figure 2B shows that CD40L expression was induced on similar percentages of CD4 + , DN and CD8a + iNKT cells in a dose-dependant manner upon activation, indicating that these iNKT cell subsets have similar potential for interacting with other cells, such as B cells and iDC.
Since CD25 was found to be expressed by significant numbers of expanded CD4 + iNKT cells ( Fig. 2A) , we next determined the frequencies of iNKT cell subsets that express the natural Treg cell phenotype, FoxP3 + CD25 + (Fig. 2C) . A significant proportion of Cytolytic degranulation by iNKT cell subsets in response to aGalCer presented by K562, Jurkat and mock-and CD1d-transfected HeLa cells was assayed by analysis of CD107a externalization. Figure 3A shows that degranulation by CD4 + ,
DN and CD8a
+ iNKT cells only occurred when CD1d was present, since CD107a expression was undetectable when the CD1d-negative cell lines K562 cells (Fig. 3A, left panel) or HeLamock (not shown) were used as targets. All three iNKT cell subsets showed an a-GalCer dose-dependent increase in CD107a expression in response to the CD1d-transfected HeLa cells and the CD1d + Jurkat cell line ( Figure 3A , centre and right panels). Optimal CD107a expression by all 3 iNKT subsets occurred when 100 ng/ml a-GalCer was used. CD8a
+ iNKT cells consistently expressed CD107a at higher frequencies than the other iNKT cell 
, CD8a
+ and DN iNKT cell subsets from 3 donors which were allowed to rest by culturing for 5 days in the absence of IL-2. Quadrants delineating positivity and negativity for CD25 and FoxP3 were set using fluorescence-minus-one control mAb staining, omitting CD25 subsets, while CD4 + iNKT cells expressed this marker at the lowest frequencies (p,0.01 for HeLa-CD1d and Jurkat; KruskalWallis).
We also investigated if iNKT cell subsets displayed cytolytic degranulation when cultured with PBMC from 2 B-CLL patients. Almost all of the lymphocytes expressed the CD19 + CD5
+ leukaemia phenotype and 0% and 10.1% were positive for CD1d (data not shown). iNKT cells from 3 donors exhibited undetectable degranulation when cultured with the CD1d-negative sample. When cultured with the CD1d + sample, surface expression of CD107a by CD8a
+ iNKT cells in all three iNKT cell lines was increased almost 3-fold by the addition of a-GalCer (7.8 to 21.4%) (Fig. 3B) . In contrast, CD107a expression was only slightly induced on CD4 + and DN iNKT cells. To confirm that CD107a expression by iNKT cell subsets correlated with target cell death, we performed cytotoxicity assays employing CFSE-labelled C1R-CD1d target cells pulsed with 100 ng/ml a-GalCer or vehicle co-cultured for 4 h with highlypurified CD4 + , CD8a + and DN iNKT cells ( Figure 1C ) at E:T ratios of 5:1. Target cell death was then assessed by staining with 7-AAD. Figure 3C shows 
Expanded CD4
+ , DN and CD8a + iNKT cells have distinct cytokine secretion profiles
Highly-purified populations of CD4
+ , DN and CD8a + iNKT cells (Fig. 1F) were stimulated with medium alone, with equal numbers of iDCs or HeLa-CD1d cells (with and without 100 ng/ ml a-GalCer), or with PMA and ionomycin for 24 hours. Cellsupernatants were then harvested and assayed for IFN-c, TNFa, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p70, IL-13, IL-17a and IL-22 secretion using the FlowCytomix Multiplex kit (Fig. 4) . When stimulated with a-GalCer-pulsed iDC or HeLa-CD1d cells or with PMA and ionomycin, all iNKT cell subsets released IFN-c, with CD8a + iNKT cells secreting the highest levels, CD4 + iNKT cells secreting the lowest levels and DN iNKT cells secreting intermediate levels. a-GalCer pulsed iDCs or HeLa-CD1d cells induced low-level secretion of TNF-a, with significantly higher levels induced by PMA and ionomycin, and again, CD8a
+ iNKT cells secreted the highest and CD4
+ iNKT cells secreted the lowest levels. Significant IL-6 secretion was detected when all iNKT cell subsets were co-cultured with a-GalCer-pulsed HeLa-CD1d cells but not when stimulated with a-GalCer-pulsed iDC or PMA and ionomycin, suggesting that IL-6 emanated from HeLa cells, but only when cultured with iNKT cells. Slight but consistent increases in IL-17a secretion were observed when DN iNKT cells were stimulated with a-GalCer pulsed HeLa-CD1d cells or PMA and ionomycin. IL-4, IL-5 and IL-13 were predominantly secreted by activated CD4
+ iNKT cells, while DN iNKT cells secreted intermediate levels and CD8a
+ iNKT cells secreted the lowest levels. However, contradicting previous reports [9,46] DN and CD8a
+ iNKT cells were nevertheless capable of secreting these Th2 cytokines. A novel finding in the present study is the release of IL-9 by iNKT cells and only activated CD4
+ iNKT cells were capable of secreting this cytokine under the conditions used. CD4 + iNKT cells were the only iNKT cell subset to secrete IL-10 after stimulation with PMA and ionomycin but not with a-GalCer pulsed HeLa-CD1d cells. However, co-cultures of iDC with all three iNKT cell subsets secreted IL-10, suggesting that this cytokine mainly emanates from iNKT-cell-matured DC. CD4
DN and CD8a
+ iNKT cells all secreted IL-2 when stimulated with a-GalCer-pulsed HeLa-CD1d cells or PMA and ionomycin, with the CD4 + subset secreting slightly higher levels compared to DN and CD8a + iNKT cells. All three iNKT subsets stimulated IL12p70 secretion by DC, while CD4 + and CD8a + iNKT cells, only, induced low-level secretion of IL-1b (Fig. 4) . No IL-22 was detected in supernatants of any iNKT cell subsets with any stimulation (data not shown). These data show that, under these in vitro conditions, a-GalCer-stimulated CD4 + , DN and CD8a + populations (Fig. 5A ). CD8a (Fig. 5B left panel) . All three subsets had similar frequencies of IL-4-producing cells (Fig. 5B  right panel) . Interestingly, while significant numbers of all 3 iNKT cell subsets simultaneously produced IFN-c and IL-4, singlepositivity for IFN-c was rare in the CD4 + iNKT cell subset and single-positivity for IL-4 was rare in CD8a + iNKT cells. In contrast, stimulated DN iNKT cells had an intermediate phenotype with significant percentages producing IFN-c or IL-4 only, in addition to double-positive IFNc + IL-4 + cells (Fig. 5A and  C) . Thus, CD8a
+ iNKT cells had the highest ratio of IFN-c/IL-4 producing cells followed by DN iNKT cells, with CD4
+ iNKT cells having the lowest (Fig. 5D ).
Discussion
The importance of iNKT cells in the prevention of disease and as potential therapeutic targets was first recognized with observations that mice lacking CD1d or iNKT cells are predisposed to developing cancer, autoimmune and infectious disease [6, 51] and with the discovery of a-GalCer and its beneficial effects in murine models of disease [5, 18, 19, 20] . The promising results in murine models have led to clinical trials in humans with various cancers, involving i.v. injection of a-GalCer [29] or a-GalCer-pulsed APC [26, 30] . These studies showed that iNKT-based immunotherapy is well tolerated, but the biological responses were only marginal. Subsequent therapeutic strategies involved the transfer of ex vivo expanded autologous iNKT cells alone or in combination with a-GalCer-pulsed APC [27, 28] . The expanded iNKT cells used in all studies were polyclonal mixtures of CD4
+ , DN and CD8a + iNKT cells. Since these iNKT cell subsets differ in their immunoregulatory properties and may even be mutually-inhibitory, it may be beneficial to adoptively transfer enriched iNKT cell subsets selected for desired properties. Although previous studies have compared the effector functions of different iNKT cell subsets [9, 15, [39] [40] [41] [42] [43] [44] [45] 47, 48] , many have been restricted to the analysis of fresh rather than expanded peripheral blood iNKT cells; many have compared CD4
+ and CD4 2 iNKT cells only, omitting the distinction between CD8a 2 b 2 (DN) and CD8a + b 2 (CD8a + ) subsets; most did not use DC as APC for aGalCer as was used in many clinical studies; and most were limited to the analysis of Th1 and Th2 cytokines only.
In the present study, we have systematically compared the phenotypes, cytolytic activities and cytokine profiles of ex vivo expanded human peripheral CD4 + , DN and CD8a + iNKT cells. Expanded rather than fresh iNKT cells were studied to provide information that is relevant to immunotherapy, which employs expanded iNKT cells. All 3 populations were present in PBMC, with DN iNKT cells generally being the predominant subtype followed by CD8a + iNKT cells and CD4 + iNKT cells being the least abundant. Expansion of sorted iNKT cells from 20 randomly selected donors in vitro resulted in lines containing .98% Va24
+
Vb11
+ cells with variable expression of CD4 and CD8a + . While all 3 iNKT cell subsets expanded vigorously, CD4
+ iNKT cells were the predominant subset in our expanded lines, indicating that this subset expands most readily using our methods.
Phenotypic analysis of expanded CD4 + , DN and CD8a + iNKT cells revealed that, similar to iNKT cells in resting PBMC [9, 44] , CD8a + and DN iNKT cells more frequently express cell-surface receptors such as CD56, CD161 and NKG2D that are typically found on NK cells. In accordance with this NK-like phenotype and as previously reported [39] [40] [41] [42] [43] [44] , CD8a
+ and DN iNKT cells displayed more potent cytotoxicity than CD4
+ iNKT cells against a number of CD1d + tumor cell lines, with consistently higher proportions expressing cell-surface CD107a and killing target cells. However, these cells were not capable of natural cytotoxicity, since killing was dependent on the presence of CD1d and a-GalCer. + and DN iNKT cells can also release these cytokines under the same stimulatory conditions, albeit at lower levels and lower frequencies. Analysis of dual IFN-c and IL-4 production by activated iNKT cell subsets revealed that significant proportions of all three iNKT cell subsets could simultaneously produce both cytokines, but at markedly different ratios. Thus, iNKT cells are likely to regulate the Th1/Th2 balance of immune responses by modulating the relative levels of IFN-c and IL-4, or IFN-c/IL-4 ratios, rather than simply turning on or off the production of either cytokine. While potential beneficial clinical effects of each cytokine are likely to be modified by simultaneous production of the other [19, 22, 32, 33, 48] , it is noteworthy that single positivity for IFN-c was almost exclusively found in the CD8a
+ and DN iNKT cell subsets and single positivity for IL-4 was restricted to CD4 + and DN iNKT cells. Thus, immunotherapy that exploits the immunoregulatory properties of iNKT cells may benefit from the use of sorted iNKT cell subsets with more polarized cytokine profiles.
We report here for the first time that human CD4 + iNKT cells but not CD8a
+ nor DN iNKT cells release IL-9 in response to pharmacological or glycolipid stimulation. IL-9, a key cytokine in the recruitment and activation of mast cells, is produced by subsets of Th1, Th17 and Treg cells as well as the recently-defined Th9 subset of CD4 + T cells [52] . IL-9 production by a subset of noninvariant (type 2) murine CD1d-restricted CD4 + NKT cells is associated with IgE production [53] and antigen-induced pulmonary inflammation and mast cell infiltration [54] . In view of the reported (but disputed) infiltration of CD4 + iNKT cells into the lungs of humans with bronchial asthma [55] , it is possible that CD4 + iNKT cell-derived IL-9 may play a role in the pathogenesis in some cases.
Murine and human iNKT cells have recently been reported to produce the Th17 cytokines IL-17 and IL-22 in response to aGalCer stimulation [10, 11] . Under our stimulatory conditions human DN iNKT cells, only, were capable of releasing IL-17 but IL-22 was not detected in the supernatants of any activated iNKT cell subset. We also confirm reports [34, 39, 47, 56] 
FoxP3
+ phenotypes, suggestive of a Treg cell phenotype. The suppressive role of IL-10 in Th1 and Th2 cellmediated immunity will provide a further way by which iNKT cells can modulate adaptive immunity and iNKT cell-derived IL-10 is thought to suppress tumor immunity [22, 34] and protect against diabetes [57] .
Rapid release of multiple cytokines is likely to have early influences on innate immune responses, however, iNKT cells can also contribute to adaptive immunity via stimulatory interactions with DC [13, 14, 58] , B cells [16, 17] , conventional T cells [43] and NK cells [43, 59] . Here we found that CD4
+ , DN and CD8a + iNKT cells similarly upregulate CD40L upon activation and similarly induce IL-10 and IL-12 by iDC, whereas CD4 + and CD8a + iNKT cells, only, induce IL-1b production. While all iNKT cell subsets can induce cytokine production by DC, previous studies [15, 40] have shown that CD8a + iNKT cells can also kill DC, resulting in reduced IL-12 secretion and skewed Th2 immunity.
iNKT cells can be beneficial or detrimental in different disease settings [5, 6, [18] [19] [20] [21] [22] 48] resulting from cytotoxicity-and cytokinebiased immune activities. Consequently, several groups are attempting to modulate the effector profiles of iNKT cells for therapeutic application, by modifying the cytokine environment [10, 53, 60] , mode of activation [11, 61] and structures of glycolipid antigens [35, 36, 37, 38, 58] . Our data show that therapeutic manipulation of iNKT cells may necessarily require the sorting of iNKT cells into functionally-distinct subsets. As well as selecting for desired effector functions, sorting of iNKT cell subsets could also allow selection of iNKT cells with distinct adhesion [46] and homing receptors [9, 42, 46, 47] that will promote optimal localization to the relevant sites.
